TRANSFORM-2
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
- NCT04468984 ↗
- Active, not recruiting
- AbbVie
- Focused
We haven't built an HCP commentary report on TRANSFORM-2 (navitoclax plus ruxolitinib; navitoclax in relapsed/refractory myelofibrosis) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TRANSFORM-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 3 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2), Incorporating Extension Arm C - Continued Access for Navitoclax to Roll Over Subjects From Studies M10-166, M16-109, M16-191, and M19-753
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Myelofibrosis (MF)
- Interventions
- Navitoclax; Ruxolitinib; Best Available Therapy (BAT)
- Arms
- Arm A: Navitoclax + Ruxolitinib · Experimental
- Arm B: Best Available Therapy (BAT) · Active comparator
- Arm C: Continued Access for Navitoclax · Experimental
- Enrollment
- 330 (estimated)
- Primary outcomes
- Arms A and B: Percentage of Participants who achieve Spleen Volume Reduction of at least 35% at Week 24 (SVR35W24)
- Sponsor
- AbbVie
- Start
- Aug 31, 2020
- Primary completion
- Jan 29, 2025
- Results posted
- No
- Registry record
- NCT04468984 · updated Jan 9, 2026
Publications
linked from the registry- Rampal RK, Harrison CN, Mesa R, Vannucchi AM, Shimoda K, Perkins A, Garcia JS, Reiter A, Radinoff A, Pane F, Palandri F, Lomaia E, Lee SE, Chuah HS, Passamonti F, Saydam G, Turgut M, Yoon SS, Bain EE, Lam H, Jain S, Potluri J, Kiladjian JJ. Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies. Leuk Lymphoma. 2026 Oct 7:1-11. doi: 10.1080/10428194.2026.2739358. Online ahead of print. PubMed 42842696